Pre-Symptomatic Diagnostics

"Real Time" Diagnostics

Companion Diagnostics

Impacting Precision Medicine

The diagnostic industry, worth over $120bn (post COVID) is broken...

  • It's slow
  • It's expensive
  • It's not accessible unless you present symptoms

Finding and treating diseases and disorders early reduces their negative impact on health

Early diagnostics opens the door to better precision care, improved care pathways and treatments reducing costs for better health services

Current Market

PCR

  • Expensive
  • Self testing out of reach
  • 4 hours minimum reaction time
  • Gold Standard

Lateral Flow Test

  • Low Cost
  • Point of Care
  • Self testing can be done
  • Low reliability / Inaccurate

The Solution

  • Low Cost
  • No Expensive Lab Needed
  • High Accuracy & Sensitivity
  • Real time readout
  • Digital Integration​

The Benefits

  • Point of Care
  • Self testing can be done
  • Long life / Use by date
  • No storage requirements
  • Personal and Health care

What we do!

Nano in vitro diagnostics that will facilitate precision medicine

Nanosensors that can be trained to detect diseases in humans, animals and the environment as easy as a pregnancy test

Our focus is on global challenges, impacting multi-dimensional pathways: from diagnosis to management (true personalised medicine)

Early, accurate pre symptomatic diagnostics - Global Challenges

Diseases caused by an External agent
(infectious deaths per year)

  • Sepsis – 11 million
  • Respiratory Tract Infections – 6.3 million
  • Tuberculosis - 1.5 million
  • Malaria - 0.5 million

Diseases caused by an Internal body failure
(non-infectious deaths per year)

  • Cancer – 10 million
  • Cardiovascular Diseases - 17.9 million
  • Dementia - 1.5 million
Good Health and Wellbeing

Early, accurate pre symptomatic diagnostics - Global Challenges

  • COVID, RTIs Our Industrial scale up (at home testing) 6.3 million deaths
  • Sepsis ––(acute care testing) 11 million deaths
  • Cancer (Pediatric leukemia) Our initial focus (never at home) 10 million deaths
  • Cardiovascular Diseases (at home testing) 17.9 million deaths
  • Dementia (at home testing) 1.5 million deaths
  • Tuberculosis (at home testing) 1.5 million deaths
  • Malaria (at home testing) 0.5 million deaths
  • HIV (at home testing) 1 million deaths.

NIVD Leadership

dr_sonia_trigueros

Dr Sonia Trigueros

Founder & Chief Scientific Officer

A world leader in nano-tech medicine

xavier_anglada

Xavier Anglada

Co-Founder | Head of Strategy

25+years of G2000 C-Level advisory, tech ventures entrepreneur and investor

charlie_regis

Charlie Regis

Partnerships and Investors

Global network of start up & scale up advisors, accelerators & investors

james_perry

James Perry

Commercial and Operations

Distribution network for products and technologies, Asset management and Marketing.

Advisory Team

simon_rendell

Simon Rendell

IP Portfolio

IP and Trademark Lawyer, partner at FieldFisher

onesimo_alvarez_moro

Onesimo Alvarez Moro

Financial

Venture Capital investments. CFO and CIO at Private Equity

dr_john_lee_allen

Dr John Lee Allen

Medical Tech

Investor with a background as physician, scientist, technology, entrepreneur